Literature DB >> 18623381

Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.

Heta Javeri1, Rohan Arora, Arlene M Correa, Wayne L Hofstetter, Jeffrey H Lee, Zhongxing Liao, Mary F McAleer, Dipen Maru, Manoop S Bhutani, Stephen G Swisher, Julie G Izzo, Jaffer A Ajani.   

Abstract

BACKGROUND: Patients with localized esophageal cancer (LEC) have diverse outcomes (post-therapy pathologic response, disease-free survival [DFS], and overall survival [OS]) after preoperative chemoradiation (P-CTRT), dictated also by inherent molecular heterogeneity. Whether the type of therapy influences the outcomes remains largely unanswered. It is hypothesized that induction chemotherapy (IC) or the type of cytotoxics used would not influence patient outcomes.
METHODS: In this retrospective analysis, consecutive patients with LEC who had P-CTRT were analyzed. Data were collected regarding age, sex, baseline clinical stage, location, type of cytotoxics, post-therapy pathology, DFS, and OS. IC and the type of cytotoxics used were found to be correlated with DFS, OS, and post-therapy pathologic response.
RESULTS: A total of 180 patients with LEC (119 had IC before P-CTRT, all had received 5-fluorouracil, 87 had received a taxane, and 57 had received a platinol) were analyzed. The median survival (MS) of all patients was 57.7 months and the 3-year and 5-year OS rates were 65.4% and 46.5%, respectively. The type of therapy appeared to have no influence on the outcome: IC versus no IC (P = .58) or platinol versus taxane versus platinol plus taxane (P = .63). Similarly, the type of pathologic response was not found to be influenced by IC (P = .18) or the type of cytotoxics used (P = .42). The data were similar for DFS.
CONCLUSIONS: IC or the type of cytotoxics used with radiation for patients with LEC does not appear to influence OS, DFS, or the type of pathologic response after therapy, suggesting that a plateau has been reached. It remains to be seen whether the use of biochemoradiotherapy can provide an advantage in outcome. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18623381     DOI: 10.1002/cncr.23688

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience.

Authors:  Panteleimon Kountourakis; Arlene M Correa; Wayne L Hofstetter; Jeffrey H Lee; Manoop S Bhutani; David C Rice; Ritsuko Komaki; Dipen M Maru; William A Ross; Ara Vaporciyan; Stephen G Swisher; Jaffer A Ajani
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

2.  MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Authors:  Jochen K Lennerz; Eunice L Kwak; Allison Ackerman; Michael Michael; Stephen B Fox; Kristin Bergethon; Gregory Y Lauwers; James G Christensen; Keith D Wilner; Daniel A Haber; Ravi Salgia; Yung-Jue Bang; Jeffrey W Clark; Benjamin J Solomon; A John Iafrate
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

3.  Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.

Authors:  J A Ajani; A M Correa; W L Hofstetter; D C Rice; M A Blum; A Suzuki; T Taketa; J Welsh; S H Lin; J H Lee; M S Bhutani; W A Ross; D M Maru; H A Macapinlac; J Erasmus; R Komaki; R J Mehran; A A Vaporciyan; S G Swisher
Journal:  Ann Oncol       Date:  2012-07-24       Impact factor: 32.976

4.  A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.

Authors:  Yuki Hayashi; Lianchun Xiao; Akihiro Suzuki; Mariela A Blum; Bradley Sabloff; Takashi Taketa; Dipen M Maru; James Welsh; Steven H Lin; Brian Weston; Jeffrey H Lee; Manoop S Bhutani; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani
Journal:  Eur J Cancer       Date:  2012-07-31       Impact factor: 9.162

5.  The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma.

Authors:  Peter S N van Rossum; David V Fried; Lifei Zhang; Wayne L Hofstetter; Linus Ho; Gert J Meijer; Brett W Carter; Laurence E Court; Steven H Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-11       Impact factor: 9.236

6.  Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell Carcinoma.

Authors:  Li-Ling Luo; Mian Xi; Ya-Di Yang; Qiao-Qiao Li; Lei Zhao; Peng Zhang; Shi-Liang Liu; Meng-Zhong Liu
Journal:  J Cancer       Date:  2017-09-20       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.